PhaseFolio is excited to begin working with EB Research Partnership (EBRP), the largest global organization dedicated to funding research to treat and cure epidermolysis bullosa.
EBRP is building its portfolio-valuation workflow at exactly the point PhaseFolio was designed to help: turning complex program data and assumptions into structured, comparable analysis.
The EBRP team will use PhaseFolio to examine valuation assumptions, compare scenarios, organize supporting evidence, and evaluate research programs at both the asset and portfolio level. Their team will also provide candid product and workflow feedback as we continue developing PhaseFolio for sophisticated biotech evaluation.
We are grateful for the opportunity to support an organization applying scientific rigor and disciplined capital allocation to one of the most urgent challenges in rare disease.
Access is being provided on a complimentary basis through PhaseFolio’s nonprofit access program.